enzalutamide

Pre-clinicalCompleted

0 watching 0 views this week💤 Quiet

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Castration-resistant Prostate Cancer

Conditions

Castration-resistant Prostate Cancer

Trial Timeline

Nov 30, 2014 → Nov 30, 2018

NCT ID

NCT02669771

About enzalutamide

enzalutamide is a pre-clinical stage product being developed by Astellas Pharma for Castration-resistant Prostate Cancer. The current trial status is completed. This product is registered under clinical trial identifier NCT02669771. Target conditions include Castration-resistant Prostate Cancer.

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (20)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05404139	Phase 2	Recruiting	May 24, 2023	Mar 1, 2026	Metastatic Prostate Cancer
NCT02749903	Phase 2	Active	Sep 14, 2016	Jul 5, 2028	Salivary Cancer
NCT02799745	Phase 2	Completed	Jun 9, 2016	Aug 28, 2020	Prostate Cancer
NCT02750358	Phase 2	Active	May 19, 2016	May 1, 2026	Breast Cancer
NCT02605863	Phase 2	Terminated	Jan 1, 2016	Feb 1, 2018	Bladder Cancer
NCT02384382	Phase 2	Completed	Nov 30, 2015	May 3, 2019	Prostate Carcinoma Metastatic to the Bone
NCT02441517	Approved	Terminated	Oct 28, 2015	Mar 15, 2017	Metastatic Castration Resistant Prostate Cancer
NCT02507570	Phase 2	Completed	Sep 23, 2015	Jan 18, 2019	Prostate Carcinoma Metastatic to the Bone
NCT02495974	Pre-clinical	Completed	Sep 8, 2015	Feb 8, 2019	Metastatic Castration Resistant Prostate Cancer
NCT02203695	Phase 2	Completed	Mar 28, 2015	Dec 31, 2022	Adenocarcinoma of the Prostate
NCT02288936	Phase 2	Completed	Feb 5, 2015	Jul 22, 2019	Hormone-refractory Prostate Cancer
NCT02669771	Pre-clinical	Completed	Nov 30, 2014	Nov 30, 2018	Castration-resistant Prostate Cancer
NCT02124668	Phase 2	Completed	Sep 23, 2014	May 25, 2017	Castration-Resistant Prostate Cancer
NCT03297385	Phase 2	Completed	Aug 28, 2014	Apr 1, 2017	Prostate Cancer
NCT02116582	Approved	Completed	May 23, 2014	Sep 29, 2017	Metastatic Castration-Resistant Prostate Cancer
NCT02099864	Phase 2	Completed	Feb 5, 2014	Jul 8, 2024	Castration-Resistant Prostate Carcinoma
NCT01977651	Approved	Completed	Sep 25, 2013	Jan 11, 2019	Metastatic Castration-resistant Prostate Cancer (mCRPC)
NCT02138162	Phase 1	Completed	Aug 1, 2013	Mar 1, 2014	Severe Hepatic Impairment
NCT01889238	Phase 2	Completed	Jun 12, 2013	Jan 10, 2024	Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
NCT01663415	Phase 2	Withdrawn	Aug 1, 2012	Oct 1, 2014	Metastatic Castration-Resistant Prostate Cancer

Competing Products

20 competing products in Castration-resistant Prostate Cancer

See all competitors

Product	Company	Stage	Hype Score
SRF617 + etrumadenant + zimberelimab	Coherus BioSciences	Phase 2	44
Docetaxel + Ifinatamab Deruxtecan + MK-5684 + Abiraterone + Enzalutamide + Rescue Medication	Daiichi Sankyo	Phase 1/2	41
Valemetostat + Darolutamide	Daiichi Sankyo	Phase 1	33
Enzalutamide	Astellas Pharma	Phase 2	52
enzalutamide + abiraterone acetate + prednisone	Astellas Pharma	Phase 2	52
Crizotinib + Enzalutamide	Astellas Pharma	Phase 1	33
Enzalutamide	Astellas Pharma	Phase 2	52
Lu-PSMA + Enzalutamide	Astellas Pharma	Phase 2	52
Enzalutamide	Astellas Pharma	Approved	85
Enzalutamide + Flutamide	Astellas Pharma	Phase 2	52
Enzalutamide + Abiraterone acetate	Astellas Pharma	Pre-clinical	23
Enzalutamide	Astellas Pharma	Approved	85
Enzalutamide	Astellas Pharma	Phase 2	52
MDV3100	Astellas Pharma	Pre-clinical	23
Enzalutamide + Placebo	Astellas Pharma	Phase 3	77
ZEN003694 + Enzalutamide	Astellas Pharma	Phase 2	52
Enfortumab vedotin	Astellas Pharma	Phase 2	52
Enzalutamide	Astellas Pharma	Phase 2	52
Enzalutamide	Astellas Pharma	Phase 2	52
Enzalutamide + Placebo	Astellas Pharma	Phase 3	77

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved

micafungin + voriconazoleApproved

mirabegron + solifenacinApproved

Zolpidem (Myslee®) + placeboApproved

TacrolimusApproved